<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100849">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942759</url>
  </required_header>
  <id_info>
    <org_study_id>BC-PET-MR-01</org_study_id>
    <nct_id>NCT01942759</nct_id>
  </id_info>
  <brief_title>Assessment of Positron Emission Tomography and Diffusion Magnetic Resonance Findings in Breast Cancer</brief_title>
  <official_title>Assessment of Positron Emission Tomography and Diffusion Magnetic Resonance Findings in Primary Lesion and Axillary Metastasis of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bagcilar Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bagcilar Training and Research Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine findings of positron emission tomography and
      diffusion weighted magnetic resonance in primary lesion and axillary metastasis of breast
      cancer and compare of two imaging modality in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aimed that to correlate both primary lesion 18F-fluorodeoxyglucose (FDG) maximum
      standardized uptake value (SUVmax) and diffusion-weighted imaging (DWI) apparent diffusion
      coefficient (ADC) with clinicopathological prognostic factors and compare the prognostic
      value of these indexes in breast cancer in this study. The evaluated and compared parameters
      are SUVmax and ADC according to age, tumour size, lymph node metastasis, receptor status,
      histologic grade, modified Nottingham prognostic index.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>To evaluate the relationships between both SUVmax and ADC and clinicopathological prognostic factors</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Histologic grade</arm_group_label>
    <description>According to the modified criteria of Bloom and Richardson grading system:  grade 1, 2 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axillary metastasis</arm_group_label>
    <description>Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified Nottingham prognostic index</arm_group_label>
    <description>NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)
The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (&gt;5.4) prognostic groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oestrogen receptor status</arm_group_label>
    <description>Negative Positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone receptor status</arm_group_label>
    <description>Negative Positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HER-2 neu status</arm_group_label>
    <description>Negative Positive</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients with breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosis of breast cancer for which surgical intervention is planned

        Exclusion Criteria:

          -  patients received neoadjuvant chemotherapy

          -  before breast surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AYNUR OZEN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bagcilar Training &amp; Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aynur Ozen, MD</last_name>
    <phone>00 90 212 440 40 00</phone>
    <email>ozenaynur@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bagcilar Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aynur Ozen, MD</last_name>
      <phone>00 90 212 440 40 00</phone>
      <email>ozenaynur@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 11, 2013</lastchanged_date>
  <firstreceived_date>September 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bagcilar Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Aynur Ozen</investigator_full_name>
    <investigator_title>Aynur Ozen</investigator_title>
  </responsible_party>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Diffusion Magnetic Resonance Imaging</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
